STOCK TITAN

Merus N.V. Common Shares - MRUS STOCK NEWS

Welcome to our dedicated page for Merus N.V. Common Shares news (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus N.V. Common Shares stock.

Merus N.V. (Nasdaq: MRUS) is a clinical-stage immuno-oncology company focused on creating innovative therapies to treat and potentially cure cancer. At the heart of Merus' approach is its proprietary Biclonics® and Triclonics® technology platforms, which generate full-length human bispecific and trispecific antibodies. These advanced therapeutics are designed to engage the immune system to kill tumor cells and inhibit tumor cell growth pathways simultaneously.

Core Business

Merus' core business revolves around the discovery and development of bispecific antibody therapeutics. Their flagship technology, Biclonics®, can attack tumors in multiple ways, making them highly effective against various cancer types. The company’s portfolio includes several promising candidates, such as MCLA-128, which targets HER2 and HER3 receptors in gastric and breast cancers; MCLA-117, targeting AML; MCLA-158 (petosemtamab), focused on head and neck squamous cell carcinoma; and MCLA-145, developed for solid tumors.

Latest Achievements and News

As of May 2024, Merus has received the FDA's Breakthrough Therapy Designation (BTD) for petosemtamab in treating patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that has progressed after treatment with platinum-based chemotherapy and PD-1/PD-L1 antibodies. This significant milestone is based on the promising data from the ongoing phase 1/2 trial of petosemtamab as a monotherapy, showing substantial improvement in clinically significant endpoints. Furthermore, Merus has announced plans to initiate a phase 3 trial in mid-2024 to evaluate the combination of petosemtamab and pembrolizumab in previously untreated patients.

Additionally, Merus revealed the acceptance of abstracts for MCLA-145 and MCLA-129 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These presentations highlighted the clinical activity of MCLA-145 in advanced solid tumors and the efficacy of MCLA-129 in non-small cell lung cancer (NSCLC).

Financial Condition and Partnerships

Merus has a solid financial foundation, bolstered by strategic partnerships and collaborations. Notably, Merus collaborates with Betta Pharmaceuticals to develop MCLA-129 in China while retaining global rights outside China. The company’s financial strategy includes advancing its clinical development programs and supporting preclinical research and technology development through successful capital raises.

About Merus N.V.

Merus N.V. is dedicated to the development of multispecific antibody therapeutics, referred to as Multiclonics®. These therapeutics have been observed in preclinical and clinical studies to exhibit the same features as conventional human monoclonal antibodies, including long half-life and low immunogenicity. For more information, visit Merus’ official website, Twitter, and LinkedIn.

Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg will speak at the Stifel 2022 Healthcare Conference on November 16, 2022, at 1:50 p.m. ET. The presentation will be available via webcast on the company's Investors page and archived for later viewing. Merus specializes in developing full-length multispecific antibodies, known as Biclonics® and Triclonics®, with potential applications in oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
conferences
-
Rhea-AI Summary

Merus N.V. (MRUS) has provided a clinical and financial update for Q3 2022. Their lead program, MCLA-129, shows clinical activity with promising early efficacy data presented at the ENA Symposium. The FDA recommends further patient enrollment in the eNRGy trial for Zenocutuzumab (Zeno) to support a Biologics License Application (BLA) for NRG1+ cancers. Collaboration revenue decreased by $7.1 million year-over-year. Operating expenses increased, leading to a greater net loss of $24.6 million. As of September 30, 2022, Merus has $372.9 million in cash, sufficient to fund operations beyond 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.02%
Tags
-
Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS) has reported interim clinical data for MCLA-129, a bispecific antibody targeting EGFR and c-MET. The phase 1/2 trial showed a favorable safety profile with no dose-limiting toxicities. Antitumor activity was noted in heavily pretreated patients across various tumor types, including confirmed partial responses. The initial recommended dose for phase 2 is set at 1500 mg biweekly. Key details will be discussed in an investor call on October 26. These findings highlight MCLA-129's potential efficacy as a treatment for advanced solid tumors, including non-small cell lung cancer (NSCLC).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.81%
Tags
none
Rhea-AI Summary

Merus N.V. (MRUS) announced promising results from the phase 1/2 trial of MCLA-129, a bispecific antibody targeting EGFR and c-MET for advanced non-small cell lung cancer (NSCLC). The drug was well-tolerated, with no dose-limiting toxicities observed. Preliminary data showed anti-tumor activity in 13 evaluable patients, with two achieving partial responses. The recommended phase 2 dose is 1500 mg. Further data will be presented at the ENA Symposium on October 28, 2022, along with an investor call detailing the program update on October 26, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.73%
Tags
none
-
Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS) announced the selection of an abstract for a poster presentation at the 34th EORTC/NCI/AACR Symposium, scheduled for October 28, 2022. The poster will focus on MCLA-129, a bispecific antibody targeting EGFR and c-MET, currently in phase 1/2 study for advanced non-small cell lung cancer (NSCLC) and other solid tumors. Preclinical studies suggest MCLA-129 may effectively treat TKI-resistant NSCLC. The abstract will be available on October 12, 2022, and the poster can be accessed during the conference and on Merus' website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.35%
Tags
none
-
Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology firm, announced that CEO Bill Lundberg will participate in a panel at Citi's 17th Annual BioPharma Conference on September 8, 2022, at 2:40 p.m. ET. This event highlights the company's innovative work in developing multispecific antibodies, including Biclonics® and Triclonics®. A live webcast will be available on the company’s investor page, and an archive of the presentation will be accessible for a limited time post-event.

For more details, visit Merus’ website and social media channels.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.76%
Tags
conferences
Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS) reported a strong clinical update for its lead bispecific antibody, zenocutuzumab (Zeno), demonstrating a 34% overall response rate in NRG1+ cancer patients at the 2022 ASCO meeting. The company anticipates MCLA-129 and petosemtamab (Peto) updates in late 2022 and early 2023, respectively. Financially, Merus ended Q2 2022 with $396.8 million in cash, enough to fund operations beyond 2024, while collaboration revenue increased to $12.7 million. However, operating losses rose, totaling $31.1 million for the quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.93%
Tags
-
Rhea-AI Summary

Merus N.V. (MRUS) announced interim data from the phase 1/2 eNRGy trial of its bispecific antibody, Zeno, aimed at treating NRG1+ cancer. Key findings include a 34% overall response rate in 79 evaluable patients, with a median duration of response at 9.1 months. Tumor reduction was observed in 70% of patients, and Zeno was noted to be well-tolerated. These results position Zeno as a potential new standard of care. An investor call is scheduled for June 5, 2022 to discuss these findings further.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS) will participate in a fireside chat at the Jefferies Healthcare Conference on June 10, 2022, at 12:45 p.m. ET. Bill Lundberg, M.D., the President and CEO, will represent the clinical-stage oncology company known for developing innovative multispecific antibodies, including Biclonics® and Triclonics®. A webcast of the event can be accessed on the Company's Investors page, and an archived version will be available post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.28%
Tags
conferences
Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS) announced positive interim results from its phase 1/2 eNRGy trial of zenocutuzumab (Zeno) for NRG1+ cancers. The data shows a robust 34% overall response rate and a median duration of response of 9.1 months. The treatment is well-tolerated, with efficacy observed across multiple NRG1+ tumor types. An oral presentation is scheduled for June 5, 2022, at ASCO, with an investor call also planned the same day to discuss these findings. The trial focuses on safety and anti-tumor activity of Zeno monotherapy in various NRG1+ cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.55%
Tags
none

FAQ

What is the current stock price of Merus N.V. Common Shares (MRUS)?

The current stock price of Merus N.V. Common Shares (MRUS) is $41.85 as of December 20, 2024.

What is the market cap of Merus N.V. Common Shares (MRUS)?

The market cap of Merus N.V. Common Shares (MRUS) is approximately 2.9B.

What is the core business of Merus N.V.?

Merus N.V. focuses on creating innovative therapies to treat and potentially cure cancer using its proprietary Biclonics® and Triclonics® platforms, which generate full-length human bispecific and trispecific antibodies.

What are some of Merus' key product candidates?

Key product candidates include MCLA-128 for gastric and breast cancers, MCLA-117 for AML, MCLA-158 (petosemtamab) for head and neck squamous cell carcinoma, and MCLA-145 for solid tumors.

What significant recent achievement has Merus reported?

Merus received the FDA’s Breakthrough Therapy Designation (BTD) for petosemtamab in treating recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that progressed after platinum-based chemotherapy and PD-1/PD-L1 antibodies.

What are Biclonics®?

Biclonics® are bispecific antibodies that can attack tumors in multiple ways, such as activating the immune system and directly inhibiting tumor cell growth pathways.

What is the status of MCLA-145 and MCLA-129?

Both MCLA-145 and MCLA-129 have shown promising clinical activity and were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, with MCLA-145 addressing solid tumors and MCLA-129 targeting non-small cell lung cancer (NSCLC).

What are Multiclonics®?

Multiclonics® are full-length human bispecific and trispecific antibody therapeutics developed by Merus, exhibiting long half-life and low immunogenicity similar to conventional human monoclonal antibodies.

Who are Merus' key partners?

One of Merus' notable partners is Betta Pharmaceuticals, which collaborates on developing MCLA-129 in China, while Merus retains global rights outside China.

What are the financial strategies of Merus?

Merus' financial strategies include advancing clinical development programs, supporting preclinical research, and raising capital through offerings, backed by strong partnerships and collaborations.

What is the purpose of the latest capital raise by Merus?

The latest capital raise aims to advance the clinical development of Merus' product candidates, support preclinical research and technology development, and for general corporate purposes.

Where can I find more information about Merus N.V.?

For more information, visit Merus’ official website, Twitter, and LinkedIn pages.

Merus N.V. Common Shares

Nasdaq:MRUS

MRUS Rankings

MRUS Stock Data

2.89B
66.39M
2.03%
105.65%
12.79%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
3584 CM UTRECHT